← Leaderboards
Jeffrey Benner
Drug Delivery Company, Llc, The
$6,616,062
Attributed
$13,232,124
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,232,124 · 3
By mechanism
UG3$8,717,301 · 2
UH3$4,514,823 · 1
Top collaborators
- Steven M Cohen5 shared
Most similar at Drug Delivery Company, Llc, The
Same institution · by research overlap
- Steven M Cohen$6,616,062
Others in their field
Other Emerging Leaders on “Pathway Interactions”
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Kevin Urdahl · Seattle Children'S Hospital$47,227,116
- Urs Ochsner · Crestone, Inc.$38,569,476
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jeffrey Glenn · Stanford University$26,017,226
Research focus
Pathway InteractionsPhase I Clinical TrialsInjectionsOpioid Use DisorderPharmaceutical PreparationsPhase 1 StudyFormulationImplantationIn VitroNaltrexoneEngineeringCanis FamiliarisDrug ImplantsDrug Delivery SystemsAnimalsExcisionHealthy VolunteerImplantDrug KineticsInvestigational DrugsDoseIn VivoDesignPhase Ii Clinical Trials
Grant awards (5)
Development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for opioid use disorder$2,932,500
UG3 · FY2025 · DA
A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder$2,708,703
UH3 · FY2025 · DA
A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder$1,806,120
UH3 · FY2024 · DA
A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder$2,700,832
UG3 · FY2020 · DA
A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder$3,083,969
UG3 · FY2019 · DA